V Wealth Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

V Wealth Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,456	Closed	-$311K	–	207
2017 Q4	$311K	Buy	2,456 +126	+5%	+$15.8K	0.16%	147
2017 Q3	$277K	Buy	2,330 +2,230	+2,230%	+$190K	0.14%	141
2017 Q2	$8K	Buy	+100	New	+$6.39K	﹤0.01%	597

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

V Wealth Advisors's ALNY Position: Q1 2018 in Review

V Wealth Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2018, closing a stake of 2,456 shares — an estimated $311K sold.

V Wealth Advisors first reported a position in ALNY in Q2 2017 and held it in 3 quarters. The position peaked at $311K in Q4 2017. 293 funds tracked by Wall St. Rank hold ALNY as of Q1 2018.

V Wealth Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
V Wealth Advisors sold 2,456 Alnylam Pharmaceuticals shares in Q1 2018, an estimated $311K.
V Wealth Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2017 and held it in 3 quarters.
V Wealth Advisors's Alnylam Pharmaceuticals position peaked at $311K in Q4 2017.
293 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2018.

Based on V Wealth Advisors's 13F filing for Q1 2018, filed 11 Apr 2018.